AbbVie reported that sales from Ubrelvy and a similar migraine medication called Qulipta, generated $1.223billion in revenue for the company in 2023. This is not the first time the agency has ...

AbbVie has carved out a niche for its migraine drug Qulipta in a competitive market, after claiming FDA approval for the product in the prevention of chronic migraine. Qulipta (atogepant ...

The 778-subject PROGRESS trial tested Qulipta in migraine patients who had been experiencing headache on 15 or more days per month, for at least three months, with AbbVie's drug given as either 60 ...